FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048703025> ?p ?o ?g. }

• W3048703025 abstract "Giardiasis, caused by the intestinal parasite Giardia lamblia, is a severe diarrheal disease, endemic in poverty-stricken regions of the world, and also a common infection in developed countries. The available therapeutic options are associated with adverse effects, and G. lamblia resistance to the standard-of-care drugs is spreading. Fumagillin, an antimicrosporidiosis drug, is a therapeutic agent with potential for the treatment of giardiasis. However, it exhibits considerable, albeit reversible, toxicity when used to treat immunocompromised microsporidiosis patients. Fumagillin is also a highly unstable compound. To address these liabilities, we designed and synthesized stable fumagillol derivatives with lower levels of permeation across polarized epithelial Caco-2 cells and better potency against G. lamblia trophozoites than fumagillin. Metronidazole-resistant G. lamblia strains were also susceptible to the new fumagillol derivatives. In addition, these compounds were more potent against the amebiasis-causing parasite Entamoeba histolytica than fumagillin. Two compounds exhibited better thermal and acid stability than fumagillin, which should prolong the drug shelf life and reduce compound degradation in the stomach. Studies with a mouse model of giardiasis with the most stable compound, 4-(((((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl)oxy)carbonyl)amino)benzoic acid (compound 9), revealed that it had better efficacy (effective dose [ED]) than fumagillin at both the fully curative dose (the 100% ED) of 6.6 mg/kg of body weight and a 50% ED of 0.064 mg/kg. Plasma pharmacokinetics revealed the slow absorption of compound 9 through the gut, consistent with the in vitro characterization in Caco-2 cells. An acute-dose study yielded a maximum tolerated dose (MTD) of 1,500 mg/kg, 227-fold higher than the fully curative dose. Thus, along with improved stability, compound 9 also exhibited an excellent therapeutic window." @default.
• W3048703025 created "2020-08-18" @default.
• W3048703025 creator A5001462157 @default.
• W3048703025 creator A5045491706 @default.
• W3048703025 creator A5058059496 @default.
• W3048703025 creator A5072432337 @default.
• W3048703025 date "2020-09-21" @default.
• W3048703025 modified "2023-10-14" @default.
• W3048703025 title "Discovery and Preclinical Development of Antigiardiasis Fumagillol Derivatives" @default.
• W3048703025 cites W1515959721 @default.
• W3048703025 cites W1799977528 @default.
• W3048703025 cites W1969558402 @default.
• W3048703025 cites W1970240947 @default.
• W3048703025 cites W1978910586 @default.
• W3048703025 cites W1989199091 @default.
• W3048703025 cites W1990381186 @default.
• W3048703025 cites W1992025104 @default.
• W3048703025 cites W2004637478 @default.
• W3048703025 cites W2010435021 @default.
• W3048703025 cites W2012090359 @default.
• W3048703025 cites W2014037304 @default.
• W3048703025 cites W2018416180 @default.
• W3048703025 cites W2020434511 @default.
• W3048703025 cites W2021869123 @default.
• W3048703025 cites W2034434671 @default.
• W3048703025 cites W2034646776 @default.
• W3048703025 cites W2041525960 @default.
• W3048703025 cites W2057687973 @default.
• W3048703025 cites W2059414029 @default.
• W3048703025 cites W2070505319 @default.
• W3048703025 cites W2070685035 @default.
• W3048703025 cites W2072300064 @default.
• W3048703025 cites W2072920353 @default.
• W3048703025 cites W2076227819 @default.
• W3048703025 cites W2077752559 @default.
• W3048703025 cites W2078727354 @default.
• W3048703025 cites W2079991727 @default.
• W3048703025 cites W2085313140 @default.
• W3048703025 cites W2085785716 @default.
• W3048703025 cites W2094220461 @default.
• W3048703025 cites W2097357567 @default.
• W3048703025 cites W2104172253 @default.
• W3048703025 cites W2107257265 @default.
• W3048703025 cites W2108494831 @default.
• W3048703025 cites W2111878357 @default.
• W3048703025 cites W2116106523 @default.
• W3048703025 cites W2123687196 @default.
• W3048703025 cites W2123845161 @default.
• W3048703025 cites W2124964277 @default.
• W3048703025 cites W2130091680 @default.
• W3048703025 cites W2139266313 @default.
• W3048703025 cites W2139425464 @default.
• W3048703025 cites W2139589162 @default.
• W3048703025 cites W2145668345 @default.
• W3048703025 cites W2152173141 @default.
• W3048703025 cites W2152477480 @default.
• W3048703025 cites W2152955833 @default.
• W3048703025 cites W2156562528 @default.
• W3048703025 cites W2160454557 @default.
• W3048703025 cites W2165711991 @default.
• W3048703025 cites W2168703816 @default.
• W3048703025 cites W2171409436 @default.
• W3048703025 cites W2307060431 @default.
• W3048703025 cites W2519249305 @default.
• W3048703025 cites W2610557350 @default.
• W3048703025 cites W2730235 @default.
• W3048703025 cites W2793264465 @default.
• W3048703025 cites W2916778917 @default.
• W3048703025 cites W39323699 @default.
• W3048703025 cites W4249091668 @default.
• W3048703025 cites W825550809 @default.
• W3048703025 doi "https://doi.org/10.1128/aac.00582-20" @default.
• W3048703025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7508583" @default.
• W3048703025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32778548" @default.
• W3048703025 hasPublicationYear "2020" @default.
• W3048703025 type Work @default.
• W3048703025 sameAs 3048703025 @default.
• W3048703025 citedByCount "5" @default.
• W3048703025 countsByYear W30487030252022 @default.
• W3048703025 countsByYear W30487030252023 @default.
• W3048703025 crossrefType "journal-article" @default.
• W3048703025 hasAuthorship W3048703025A5001462157 @default.
• W3048703025 hasAuthorship W3048703025A5045491706 @default.
• W3048703025 hasAuthorship W3048703025A5058059496 @default.
• W3048703025 hasAuthorship W3048703025A5072432337 @default.
• W3048703025 hasBestOaLocation W30487030251 @default.
• W3048703025 hasConcept C126322002 @default.
• W3048703025 hasConcept C18903297 @default.
• W3048703025 hasConcept C2776309324 @default.
• W3048703025 hasConcept C2776867272 @default.
• W3048703025 hasConcept C2776908094 @default.
• W3048703025 hasConcept C2777396551 @default.
• W3048703025 hasConcept C2780394083 @default.
• W3048703025 hasConcept C2780626423 @default.
• W3048703025 hasConcept C501593827 @default.
• W3048703025 hasConcept C71924100 @default.
• W3048703025 hasConcept C86803240 @default.
• W3048703025 hasConcept C89423630 @default.
• W3048703025 hasConcept C98274493 @default.
• W3048703025 hasConceptScore W3048703025C126322002 @default.

• next